{
    "abstract": "Background H7 influenza strains can cause severe and often fatal human infections, especially in the elderly. This phase II, observer-blind, randomized trial (www.ClinicalTrials.gov: NCT01949090) assessed the immunogenicity and safety of a novel AS03-adjuvanted H7N1 vaccine that may serve as a model H7-subtype vaccine. Methods 360 adults \u226565\u00a0years of age in stable health received either 1 of 4 adjuvanted A/mallard/Netherlands/12/2000 split virion vaccine formulations (3.75\u00a0\u03bcg or 7.5\u00a0\u03bcg hemagglutinin adjuvanted with either AS03A or AS03B) or saline placebo, given as a 2-dose series. Immunogenicity was assessed using hemagglutination-inhibition (HI) and microneutralization (MN) assays for the per-protocol cohort, comprising 332 participants at 21\u00a0days post-each dose, 332 at month 6, and 309 at month 12 (HI assay only). Safety was assessed up to month 12 for all participants who had received \u22651 dose (360 participants). Results For H7N1 HI antibody assessment at day 42 (21\u00a0days post-dose 2), seroprotection rates (SPR) in the vaccinated groups were 69.6%\u201388.7%, seroconversion rates (SCR) 69.6%\u201388.5%, mean geometric increase (MGI) 11.0\u201318.9, and HI geometric mean titers (GMTs) 55.0\u2013104.8. These parameters declined by month 6 and month 12. Microneutralization GMTs were 46.2\u201374.7 in the vaccinated groups at day 42, while vaccine response rate (VRR; proportion with \u22654-fold increase in MN titer) was 46.4%\u201381.5%. For the cross-reactive H7N9 strain, at day 42, HI GMT were 64.3\u2013201.3, SPR 78.6%\u201396.3%, SCR 79.3%\u201396.3%, and MGI 14.1\u201337.7; MN GMTs were 44.0\u201385.6, and VRR 46.4\u201385.2%. The most frequent solicited symptom was injection site pain (41.7%\u201365.0% of vaccine recipients). In total, 40 participants reported 67 serious adverse events; none were considered causally related to vaccination. Conclusions In adults aged \u226565\u00a0years, the adjuvanted H7N1 vaccine was immunogenic after 2 doses, and had an acceptable safety profile. www.ClinicalTrials.gov: NCT01949090.",
    "author_highlights": [
        {
            "endOffset": 18002,
            "sentence": "AS03-adjuvanted H7N1 vaccine formulations were evaluated in adults \u226565 years of age.",
            "startOffset": 17918
        },
        {
            "endOffset": 18083,
            "sentence": "Post-dose 2, 69.6%\u201388.7% of participants per group had HI antibody titers \u22651:40.",
            "startOffset": 18003
        },
        {
            "endOffset": 18152,
            "sentence": "Cross-reactivity to a vaccine-heterologous H7N9 strain was observed.",
            "startOffset": 18084
        },
        {
            "endOffset": 18226,
            "sentence": "All H7N1 vaccine formulations had a clinically acceptable safety profile.",
            "startOffset": 18153
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Rongbao",
                    "initial": "R.",
                    "last": "Gao"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Cao"
                },
                {
                    "first": "Yunwen",
                    "initial": "Y.",
                    "last": "Hu"
                },
                {
                    "first": "Zijian",
                    "initial": "Z.",
                    "last": "Feng"
                },
                {
                    "first": "Dayan",
                    "initial": "D.",
                    "last": "Wang"
                },
                {
                    "first": "Wanfu",
                    "initial": "W.",
                    "last": "Hu"
                },
                {
                    "first": "Jian",
                    "initial": "J.",
                    "last": "Chen"
                },
                {
                    "first": "Zhijun",
                    "initial": "Z.",
                    "last": "Jie"
                },
                {
                    "first": "Haibo",
                    "initial": "H.",
                    "last": "Qiu"
                },
                {
                    "first": "Ke",
                    "initial": "K.",
                    "last": "Xu"
                },
                {
                    "first": "Xuewei",
                    "initial": "X.",
                    "last": "Xu"
                },
                {
                    "first": "Hongzhou",
                    "initial": "H.",
                    "last": "Lu"
                },
                {
                    "first": "Wenfei",
                    "initial": "W.",
                    "last": "Zhu"
                },
                {
                    "first": "Zhancheng",
                    "initial": "Z.",
                    "last": "Gao"
                },
                {
                    "first": "Nijuan",
                    "initial": "N.",
                    "last": "Xiang"
                },
                {
                    "first": "Yinzhong",
                    "initial": "Y.",
                    "last": "Shen"
                },
                {
                    "first": "Zebao",
                    "initial": "Z.",
                    "last": "He"
                },
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Gu"
                },
                {
                    "first": "Zhiyong",
                    "initial": "Z.",
                    "last": "Zhang"
                },
                {
                    "first": "Yi",
                    "initial": "Y.",
                    "last": "Yang"
                },
                {
                    "first": "Xiang",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Zhou"
                },
                {
                    "first": "Xiaodan",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Shumei",
                    "initial": "S.",
                    "last": "Zou"
                },
                {
                    "first": "Ye",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Xiyan",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Yang"
                },
                {
                    "first": "Junfeng",
                    "initial": "J.",
                    "last": "Guo"
                },
                {
                    "first": "Jie",
                    "initial": "J.",
                    "last": "Dong"
                },
                {
                    "first": "Qun",
                    "initial": "Q.",
                    "last": "Li"
                },
                {
                    "first": "Libo",
                    "initial": "L.",
                    "last": "Dong"
                },
                {
                    "first": "Yun",
                    "initial": "Y.",
                    "last": "Zhu"
                },
                {
                    "first": "Tian",
                    "initial": "T.",
                    "last": "Bai"
                },
                {
                    "first": "Shiwen",
                    "initial": "S.",
                    "last": "Wang"
                },
                {
                    "first": "Pei",
                    "initial": "P.",
                    "last": "Hao"
                },
                {
                    "first": "Weizhong",
                    "initial": "W.",
                    "last": "Yang"
                },
                {
                    "first": "Yanping",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Jun",
                    "initial": "J.",
                    "last": "Han"
                },
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Dexin",
                    "initial": "D.",
                    "last": "Li"
                },
                {
                    "first": "George F.",
                    "initial": "G.F.",
                    "last": "Gao"
                },
                {
                    "first": "Guizhen",
                    "initial": "G.",
                    "last": "Wu"
                },
                {
                    "first": "Yu",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Zhenghong",
                    "initial": "Z.",
                    "last": "Yuan"
                },
                {
                    "first": "Yuelong",
                    "initial": "Y.",
                    "last": "Shu"
                }
            ],
            "doi": "10.1056/NEJMoa1304459",
            "firstpage": "1888",
            "issn": "00284793",
            "lastpage": "1897",
            "pub_year": 2013,
            "title": "Human infection with a novel avian-origin",
            "volume": "368"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Peng",
                    "initial": "P.",
                    "last": "Wu"
                },
                {
                    "first": "Zhibin",
                    "initial": "Z.",
                    "last": "Peng"
                },
                {
                    "first": "Vicky J.",
                    "initial": "V.J.",
                    "last": "Fang"
                },
                {
                    "first": "Luzhao",
                    "initial": "L.",
                    "last": "Feng"
                },
                {
                    "first": "Tim K.",
                    "initial": "T.K.",
                    "last": "Tsang"
                },
                {
                    "first": "Hui",
                    "initial": "H.",
                    "last": "Jiang"
                },
                {
                    "first": "Eric H.Y.",
                    "initial": "E.H.Y.",
                    "last": "Lau"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Yang"
                },
                {
                    "first": "Jiandong",
                    "initial": "J.",
                    "last": "Zheng"
                },
                {
                    "first": "Ying",
                    "initial": "Y.",
                    "last": "Qin"
                },
                {
                    "first": "Zhongjie",
                    "initial": "Z.",
                    "last": "Li"
                },
                {
                    "first": "Gabriel M.",
                    "initial": "G.M.",
                    "last": "Leung"
                },
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Benjamin J.",
                    "initial": "B.J.",
                    "last": "Cowling"
                }
            ],
            "doi": "10.3201/eid2206.151752",
            "firstpage": "964",
            "issn": "10806040",
            "lastpage": "972",
            "pmid": "27191934",
            "pub_year": 2016,
            "title": "Human infection with influenza A(H7N9) virus during 3 major epidemic waves, China, 2013\u20132015",
            "volume": "22"
        },
        "b0015": {
            "authors": [
                {
                    "first": "B. J.",
                    "initial": "B.J.",
                    "last": "Cowling"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Freeman"
                },
                {
                    "first": "J. Y.",
                    "initial": "J.Y.",
                    "last": "Wong"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Wu"
                },
                {
                    "first": "Q.",
                    "initial": "Q.",
                    "last": "Liao"
                },
                {
                    "first": "E. H.",
                    "initial": "E.H.",
                    "last": "Lau"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Wu"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Fielding"
                },
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Leung"
                }
            ],
            "issn": "1025496X",
            "pmid": "23725807",
            "pub_year": 2013,
            "title": "Preliminary inferences on the age-specific seriousness of human disease caused by avian influenza A(H7N9) infections in China, March to April 2013",
            "volume": "18"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Joseph P.",
                    "initial": "J.P.",
                    "last": "Dudley"
                },
                {
                    "first": "Ian M.",
                    "initial": "I.M.",
                    "last": "Mackay"
                }
            ],
            "doi": "10.1016/j.jcv.2013.09.004",
            "firstpage": "568",
            "issn": "13866532",
            "lastpage": "570",
            "pmid": "24091087",
            "pub_year": 2013,
            "title": "Age-specific and sex-specific morbidity and mortality from avian influenza A(H7N9)",
            "volume": "58"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Benjamin J.",
                    "initial": "B.J.",
                    "last": "Cowling"
                },
                {
                    "first": "Luzhao",
                    "initial": "L.",
                    "last": "Feng"
                },
                {
                    "first": "Eric H.Y.",
                    "initial": "E.H.Y.",
                    "last": "Lau"
                },
                {
                    "first": "Qiaohong",
                    "initial": "Q.",
                    "last": "Liao"
                },
                {
                    "first": "Tim K.",
                    "initial": "T.K.",
                    "last": "Tsang"
                },
                {
                    "first": "Zhibin",
                    "initial": "Z.",
                    "last": "Peng"
                },
                {
                    "first": "Peng",
                    "initial": "P.",
                    "last": "Wu"
                },
                {
                    "first": "Fengfeng",
                    "initial": "F.",
                    "last": "Liu"
                },
                {
                    "first": "Vicky J.",
                    "initial": "V.J.",
                    "last": "Fang"
                },
                {
                    "first": "Honglong",
                    "initial": "H.",
                    "last": "Zhang"
                },
                {
                    "first": "Ming",
                    "initial": "M.",
                    "last": "Li"
                },
                {
                    "first": "Lingjia",
                    "initial": "L.",
                    "last": "Zeng"
                },
                {
                    "first": "Zhen",
                    "initial": "Z.",
                    "last": "Xu"
                },
                {
                    "first": "Zhongjie",
                    "initial": "Z.",
                    "last": "Li"
                },
                {
                    "first": "Huiming",
                    "initial": "H.",
                    "last": "Luo"
                },
                {
                    "first": "Qun",
                    "initial": "Q.",
                    "last": "Li"
                },
                {
                    "first": "Zijian",
                    "initial": "Z.",
                    "last": "Feng"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Cao"
                },
                {
                    "first": "Weizhong",
                    "initial": "W.",
                    "last": "Yang"
                },
                {
                    "first": "Joseph T.",
                    "initial": "J.T.",
                    "last": "Wu"
                },
                {
                    "first": "Yu",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Gabriel M.",
                    "initial": "G.M.",
                    "last": "Leung"
                }
            ],
            "doi": "10.1016/S0140-6736(13)61207-6",
            "firstpage": "138",
            "issn": "01406736",
            "lastpage": "145",
            "pmid": "23803487",
            "pub_year": 2013,
            "title": "Human infection with avian influenza A H7N9 virus: An assessment of clinical severity",
            "volume": "382"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Adrian J.",
                    "initial": "A.J.",
                    "last": "Reber"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Chirkova"
                },
                {
                    "first": "Jin Hyang",
                    "initial": "J.H.",
                    "last": "Kim"
                },
                {
                    "first": "Weiping",
                    "initial": "W.",
                    "last": "Cao"
                },
                {
                    "first": "Renata",
                    "initial": "R.",
                    "last": "Biber"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Shay"
                },
                {
                    "first": "Suryaprakash",
                    "initial": "S.",
                    "last": "Sambhara"
                }
            ],
            "firstpage": "68",
            "issn": "21525250 ",
            "lastpage": "90",
            "pub_year": 2012,
            "title": "Immunosenescence and challenges of vaccination against influenza in the aging population",
            "volume": "3"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "James D.",
                    "initial": "J.D.",
                    "last": "Campbell"
                },
                {
                    "first": "Sharon E.",
                    "initial": "S.E.",
                    "last": "Frey"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Kotloff"
                },
                {
                    "first": "Andrea A.",
                    "initial": "A.A.",
                    "last": "Berry"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "Graham"
                },
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Buddy Creech"
                },
                {
                    "first": "Isaac P.",
                    "initial": "I.P.",
                    "last": "Thomsen"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Andres F.",
                    "initial": "A.F.",
                    "last": "Gutierrez"
                },
                {
                    "first": "Edwin L.",
                    "initial": "E.L.",
                    "last": "Anderson"
                },
                {
                    "first": "Hana M.",
                    "initial": "H.M.",
                    "last": "El Sahly"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Hill"
                },
                {
                    "first": "Diana L.",
                    "initial": "D.L.",
                    "last": "Noah"
                },
                {
                    "first": "Abbie R.",
                    "initial": "A.R.",
                    "last": "Bellamy"
                }
            ],
            "doi": "10.1001/jama.2015.7916",
            "firstpage": "237",
            "issn": "00987484",
            "lastpage": "246",
            "pmid": "26197184",
            "pub_year": 2015,
            "title": "Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response a randomized clinical trial",
            "volume": "314"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Anuradha",
                    "initial": "A.",
                    "last": "Madan"
                },
                {
                    "first": "Murdo",
                    "initial": "M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Segall"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Chu"
                },
                {
                    "first": "Azhar",
                    "initial": "A.",
                    "last": "Toma"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Rheault"
                },
                {
                    "first": "Damien",
                    "initial": "D.",
                    "last": "Friel"
                },
                {
                    "first": "Jyoti",
                    "initial": "J.",
                    "last": "Soni"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.01.054",
            "firstpage": "1431",
            "issn": "0264410X",
            "lastpage": "1439",
            "pmid": "28187952",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial",
            "volume": "35"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Caldwell"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Gilderman"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Berwald"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Fogarty"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Poling"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Riff"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Shepard"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Brune"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Ferguson"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Vaughn"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                }
            ],
            "doi": "10.1093/infdis/jir172",
            "firstpage": "1729",
            "issn": "00221899",
            "lastpage": "1738",
            "pmid": "21606531",
            "pub_year": 2011,
            "title": "Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: A phase III, placebo-controlled, randomized study",
            "volume": "203"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Ferguson"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Riff"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                },
                {
                    "first": "Casey",
                    "initial": "C.",
                    "last": "Johnson"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Kenney"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Innis"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                }
            ],
            "doi": "10.1086/652701",
            "firstpage": "1644",
            "issn": "00221899",
            "lastpage": "1653",
            "pmid": "20423222",
            "pub_year": 2010,
            "title": "Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: A randomized controlled phase 1/2 trial in adults",
            "volume": "201"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Anuradha",
                    "initial": "A.",
                    "last": "Madan"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Segall"
                },
                {
                    "first": "Murdo",
                    "initial": "M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Robin",
                    "initial": "R.",
                    "last": "Kroll"
                },
                {
                    "first": "Damien",
                    "initial": "D.",
                    "last": "Friel"
                },
                {
                    "first": "Jyoti",
                    "initial": "J.",
                    "last": "Soni"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                }
            ],
            "doi": "10.1093/infdis/jiw414",
            "firstpage": "1717",
            "issn": "00221899",
            "lastpage": "1727",
            "pmid": "27609809",
            "pub_year": 2016,
            "title": "Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults",
            "volume": "214"
        },
        "b0060": {
            "authors": [
                {
                    "first": "St\u00e9phane",
                    "initial": "S.",
                    "last": "Heijmans"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "De Meulemeester"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Reynders"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Giet"
                },
                {
                    "first": "Etienne",
                    "initial": "E.",
                    "last": "Demanet"
                },
                {
                    "first": "Pierre Yves",
                    "initial": "P.Y.",
                    "last": "Devresse"
                },
                {
                    "first": "Giancarlo",
                    "initial": "G.",
                    "last": "Icardi"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Francxois",
                    "initial": "F.",
                    "last": "Roman"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Gillard"
                }
            ],
            "doi": "10.1093/infdis/jiq174",
            "firstpage": "1054",
            "issn": "00221899",
            "lastpage": "1062",
            "pmid": "21450995",
            "pub_year": 2011,
            "title": "Immunogenicity profile of a 3.75-\u03bcg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: A randomized trial",
            "volume": "203"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Gillard"
                },
                {
                    "first": "Daniel Wai Sing",
                    "initial": "D.W.S.",
                    "last": "Chu"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Pan Chyr",
                    "initial": "P.C.",
                    "last": "Yang"
                },
                {
                    "first": "Prasert",
                    "initial": "P.",
                    "last": "Thongcharoen"
                },
                {
                    "first": "Fong S.",
                    "initial": "F.S.",
                    "last": "Lim"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Walravens"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Roman"
                }
            ],
            "doi": "10.1186/1471-2334-14-142",
            "issn": "14712334",
            "pmid": "24628789",
            "pub_year": 2014,
            "title": "Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults",
            "volume": "14"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Corey P.",
                    "initial": "C.P.",
                    "last": "Mallett"
                },
                {
                    "first": "Edith",
                    "initial": "E.",
                    "last": "Beaulieu"
                },
                {
                    "first": "Marie H\u00e9l\u00e8ne",
                    "initial": "M.H.",
                    "last": "Joly"
                },
                {
                    "first": "Beno\u00eet",
                    "initial": "B.",
                    "last": "Baras"
                },
                {
                    "first": "Xiuhua",
                    "initial": "X.",
                    "last": "Lu"
                },
                {
                    "first": "Feng",
                    "initial": "F.",
                    "last": "Liu"
                },
                {
                    "first": "Min Z.",
                    "initial": "M.Z.",
                    "last": "Levine"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.053",
            "firstpage": "3784",
            "issn": "0264410X",
            "lastpage": "3787",
            "pmid": "26100923",
            "pub_year": 2015,
            "title": "AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes",
            "volume": "33"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Ewen"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Zhou"
                },
                {
                    "first": "Kevin P.",
                    "initial": "K.P.",
                    "last": "Kane"
                },
                {
                    "first": "Dongxu",
                    "initial": "D.",
                    "last": "Xie"
                },
                {
                    "first": "W. David",
                    "initial": "W.D.",
                    "last": "Hager"
                },
                {
                    "first": "Mary Beth",
                    "initial": "M.B.",
                    "last": "Barry"
                },
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Kleppinger"
                },
                {
                    "first": "Yazhen",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "R. Chris",
                    "initial": "R.C.",
                    "last": "Bleackley"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.01.136",
            "firstpage": "2418",
            "issn": "0264410X",
            "lastpage": "2425",
            "pmid": "19368783",
            "pub_year": 2009,
            "title": "Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults",
            "volume": "27"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Jan P.",
                    "initial": "J.P.",
                    "last": "Dutz"
                }
            ],
            "doi": "10.1086/590435",
            "firstpage": "632",
            "issn": "00221899",
            "lastpage": "634",
            "pmid": "18652548",
            "pub_year": 2008,
            "title": "Better influenza vaccines for older people: What will it take?",
            "volume": "198"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Dongxu",
                    "initial": "D.",
                    "last": "Xie"
                },
                {
                    "first": "W. David",
                    "initial": "W.D.",
                    "last": "Hager"
                },
                {
                    "first": "Mary Beth",
                    "initial": "M.B.",
                    "last": "Barry"
                },
                {
                    "first": "Yazhen",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Kleppinger"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Ewen"
                },
                {
                    "first": "Kevin P.",
                    "initial": "K.P.",
                    "last": "Kane"
                },
                {
                    "first": "R. Chris",
                    "initial": "R.C.",
                    "last": "Bleackley"
                }
            ],
            "doi": "10.4049/jimmunol.176.10.6333",
            "firstpage": "6333",
            "issn": "00221767",
            "lastpage": "6339",
            "pmid": "16670345",
            "pub_year": 2006,
            "title": "T cell responses are better correlates of vaccine protection in the elderly",
            "volume": "176"
        }
    },
    "body_text": [
        {
            "endOffset": 41053,
            "parents": [],
            "secId": "s0085",
            "sentence": "This work was funded by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (HHS/BARDA; contract number HHSO100200700029C) and GlaxoSmithKline Biologicals SA.",
            "startOffset": 40827,
            "title": "Funding"
        },
        {
            "endOffset": 22902,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Persons eligible for enrolment were men and women aged \u226565 years at the time of study entry with stable health and access to a consistent means of telephone contact, for whom the investigator considered that they would comply with protocol requirements (exclusion criteria: Supplementary methods).",
            "startOffset": 22605,
            "title": "Study design and participants"
        },
        {
            "endOffset": 34281,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Only the VIIth nerve paralysis case was considered to be a pIMD by the investigator.",
            "startOffset": 34197,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 21983,
            "parents": [],
            "secId": "s0005",
            "sentence": "Addition of an adjuvant also allows antigen sparing, which is key for pandemic vaccines.",
            "startOffset": 21895,
            "title": "Introduction"
        },
        {
            "endOffset": 39180,
            "parents": [],
            "secId": "s0080",
            "sentence": "No grade-3 redness or swelling were reported.",
            "startOffset": 39135,
            "title": "Discussion"
        },
        {
            "endOffset": 25240,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "AS03 is a GSK proprietary Adjuvant System containing \u0251-tocopherol and squalene in an oil-in-water emulsion (11.86 mg tocopherol for AS03A, 5.93 mg for AS03B).",
            "startOffset": 25082,
            "title": "Study vaccine"
        },
        {
            "endOffset": 20994,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 20993,
                    "startOffset": 20988
                },
                "b0015": {
                    "endOffset": 20993,
                    "startOffset": 20988
                },
                "b0020": {
                    "endOffset": 20993,
                    "startOffset": 20988
                },
                "b0025": {
                    "endOffset": 20993,
                    "startOffset": 20988
                }
            },
            "secId": "s0005",
            "sentence": "There is a notable excess of confirmed H7N9 cases in the elderly [2\u20135].",
            "startOffset": 20923,
            "title": "Introduction"
        },
        {
            "endOffset": 39403,
            "parents": [],
            "secId": "s0080",
            "sentence": "None of the reported SAEs were considered by the investigator to be causally related to the vaccination.",
            "startOffset": 39299,
            "title": "Discussion"
        },
        {
            "endOffset": 24689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The laboratory was also blinded to the treatment, and serological data were not available during the course of the study to any investigator, the sponsor or anyone involved in data collection.",
            "startOffset": 24497,
            "title": "Blinding"
        },
        {
            "endOffset": 29729,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "For GMT calculation, an arbitrary value of half the cut-off was given to antibody titers below the cut-off.",
            "startOffset": 29622,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40820,
            "parents": [],
            "secId": "s0080",
            "sentence": "Our results support further development of H7N1 and H7N9 vaccines for this age group, which is an important target population due to the lethality and high morbidity of H7N9 infections in elderly persons.",
            "startOffset": 40616,
            "title": "Discussion"
        },
        {
            "endOffset": 30572,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "VRR for MN titers was defined as proportion of participants with either pre-vaccination (day 0) reciprocal titer <28 and post-vaccination reciprocal titer \u226556, or pre-vaccination reciprocal HI titer \u226528 and \u22654-fold increase in post-vaccination reciprocal titer against the tested virus.",
            "startOffset": 30286,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29010,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Safety analyses were performed on the total vaccinated cohort, comprising all participants who received at least 1 study dose.",
            "startOffset": 28884,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21592,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 21591,
                    "startOffset": 21588
                }
            },
            "secId": "s0005",
            "sentence": "However, immunosenescence not only leads to elderly being disproportionately affected by influenza-associated morbidity and mortality; it also poses challenges for vaccination in this age group [6].",
            "startOffset": 21394,
            "title": "Introduction"
        },
        {
            "endOffset": 20723,
            "parents": [],
            "secId": "s0005",
            "sentence": "H7 influenza virus infections have caused periodic outbreaks in poultry worldwide, with sporadic transmission to humans.",
            "startOffset": 20603,
            "title": "Introduction"
        },
        {
            "endOffset": 37725,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 37657,
                    "startOffset": 37654
                }
            },
            "secId": "s0080",
            "sentence": "Moreover, elderly persons generally have a weaker immune response to vaccination than younger adults due to immunosenescence [6], which further supports the need for a 2-dose vaccination schedule.",
            "startOffset": 37529,
            "title": "Discussion"
        },
        {
            "endOffset": 25395,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The study vaccines or placebo (0.5 mL per dose) were administered intramuscularly in the deltoid region of the arm.",
            "startOffset": 25280,
            "title": "Study vaccine"
        },
        {
            "endOffset": 24146,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Treatments were allocated by GSK\u2019s central randomization system on the Internet, using a minimization algorithm accounting for center, age (<75 years/\u226575 years) and history of seasonal influenza vaccination in the past 3 years.",
            "startOffset": 23919,
            "title": "Randomization"
        },
        {
            "endOffset": 30286,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "MGI was calculated as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer against the relevant virus strain.",
            "startOffset": 30095,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The formulations (manufactured by GSK, Quebec, Canada) contained 3.75 or 7.5 \u03bcg HA of the A/mallard/Netherlands/12/2000 NIBRG-63 strain, adjuvanted with AS03A or AS03B (both manufactured by GSK).",
            "startOffset": 24886,
            "title": "Study vaccine"
        },
        {
            "endOffset": 35040,
            "parents": [],
            "secId": "s0080",
            "sentence": "The H7N9 influenza virus has been reported to cause severe and often fatal infections, especially in the elderly.",
            "startOffset": 34927,
            "title": "Discussion"
        },
        {
            "endOffset": 26209,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Venous blood samples for immunogenicity assessment were collected at days 0, 21 and 42, and months 6 and 12.",
            "startOffset": 26101,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 30883,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, 360 participants were enrolled between 25 September 2013 and 23 October 2014; all participants received at least 1 study dose and were included in the total vaccinated cohort.",
            "startOffset": 30699,
            "title": "Study population"
        },
        {
            "endOffset": 39298,
            "parents": [],
            "secId": "s0080",
            "sentence": "Solicited general symptoms and unsolicited AEs were similarly distributed between the vaccination and placebo groups.",
            "startOffset": 39181,
            "title": "Discussion"
        },
        {
            "endOffset": 42123,
            "parents": [],
            "secId": "s0095",
            "sentence": "All authors had full access to the data and gave final approval before submission.",
            "startOffset": 42041,
            "title": "Author contribution"
        },
        {
            "endOffset": 35927,
            "parents": [],
            "secId": "s0080",
            "sentence": "After 2 doses, the HI GMT point estimates were higher for the groups receiving an AS03A formulation than those receiving an AS03B formulation (104.8 and 97.0 for H7N1-3.75A and H7N1-7.5A, respectively, compared to 55.0 and 85.5 for H7N1-3.75B and H7N1-7.5B), but the 95% CIs were overlapping.",
            "startOffset": 35635,
            "title": "Discussion"
        },
        {
            "endOffset": 25619,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Co-primary objectives were the descriptive assessment of the immune response elicited by the vaccine formulations 21 days post dose 2, and description of safety and reactogenicity through the day 42 visit.",
            "startOffset": 25414,
            "title": "Study objectives"
        },
        {
            "endOffset": 23918,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccine formulations contained 3.75 \u03bcg HA adjuvanted with AS03A (H7N1-3.75A) or AS03B (H7N1-3.75B), or 7.5 \u03bcg HA adjuvanted with AS03A (H7N1-7.5A) or AS03B (H7N1-7.5B).",
            "startOffset": 23750,
            "title": "Randomization"
        },
        {
            "endOffset": 36048,
            "parents": [],
            "secId": "s0080",
            "sentence": "A similar trend was observed between the AS03B and AS03A formulations when the immune response was assessed by MN assay.",
            "startOffset": 35928,
            "title": "Discussion"
        },
        {
            "endOffset": 23285,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial was conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki.",
            "startOffset": 23134,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41583,
            "parents": [],
            "secId": "s0090",
            "sentence": "MF declares payment from Colchester Research Group (CRG) for work as an investigator outside the submitted work.",
            "startOffset": 41471,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 31280,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "An immune response against H7N1 was elicited in all vaccine groups 21 days post-dose 2 (Fig. 2, Table 2).",
            "startOffset": 31175,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 27549,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "For the MN assay, titers <28 were considered to be below the cut-off.",
            "startOffset": 27480,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 32356,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Day 42 H7N9 HI antibody SPRs in the vaccine groups ranged from 78.6% (H7N1-3.75B) to 96.3% (H7N1-3.75A) (Table 2).",
            "startOffset": 32242,
            "title": "Immune response to the cross-reactive H7N9 strain"
        },
        {
            "endOffset": 37347,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 37346,
                    "startOffset": 37342
                }
            },
            "secId": "s0080",
            "sentence": "Thus, the authors concluded that the AS03A-adjuvanted H5N1 vaccine could be administered to elderly persons at the same dose and schedule as in younger adults [12].",
            "startOffset": 37183,
            "title": "Discussion"
        },
        {
            "endOffset": 22604,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "This study was a phase II, observer-blind, randomized, placebo-controlled, multi-center trial in the US and Canada.",
            "startOffset": 22489,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33689,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Four (6.7%) participants in the 3.75A and 7.5B groups, 2 (3.3%) in the 7.5A group, and 3 (2.5%) in the placebo group reported at least 1 grade 3 unsolicited AE; none were considered by the investigator to be vaccination-related.",
            "startOffset": 33461,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36643,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 36642,
                    "startOffset": 36638
                }
            },
            "secId": "s0080",
            "sentence": "In a study assessing AS03A-adjuvanted H5N1 vaccine in adults \u226561 years of age, the immune response was higher in participants who received a double (7.5 \u03bcg HA) dose compared to those who received a single (3.75 \u03bcg) dose: post-dose 2 GMTs were 237.3 and 126.8 for the double and single dose, respectively, while SPR were 95.9% vs. 83.6% and SCR 88.3% vs. 72.4% [12].",
            "startOffset": 36278,
            "title": "Discussion"
        },
        {
            "endOffset": 31713,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In vaccine recipients, the immune response peaked at 21 days post dose 2, and had decreased by month 6 to return to baseline at month 12 (Fig. 2).",
            "startOffset": 31567,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 31046,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The PP cohort for immunogenicity included 332 participants at day 42, 332 at month 6, and 309 at month 12 (Fig. 1); 347 participants completed the month 12 visit.",
            "startOffset": 30884,
            "title": "Study population"
        },
        {
            "endOffset": 32568,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The immune response against H7N9 over time had a similar pattern as against the vaccine H7N1 strain (Figs. 2 and 3).",
            "startOffset": 32452,
            "title": "Immune response to the cross-reactive H7N9 strain"
        },
        {
            "endOffset": 28884,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "This was a descriptive study with a target sample size of 360 participants (120 in the placebo group, 60 per vaccine group), to obtain estimates of immunogenicity and safety with adequate precision for a phase II trial; the study was not designed to test any specific hypothesis.",
            "startOffset": 28605,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38593,
            "parents": [],
            "secId": "s0080",
            "sentence": "The absence of data characterizing the cell-mediated immune response is a limitation of this study.",
            "startOffset": 38494,
            "title": "Discussion"
        },
        {
            "endOffset": 26072,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Secondary objectives included description of vaccine-homologous H7N1 hemagglutination-inhibition (HI) antibody profile in all study groups and vaccine-heterologous H7N9 HI antibody profile for a subset of participants up to month 12, description of immune response to the vaccine strain and vaccine-heterologous H7N9 microneutralization (MN) antibodies up to month 6 for a subset of participants from each group, and evaluation of safety up to month 12.",
            "startOffset": 25619,
            "title": "Study objectives"
        },
        {
            "endOffset": 24302,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Upon providing the age and subject identification number, the randomization system determined the study group and provided the treatment number to be used.",
            "startOffset": 24147,
            "title": "Randomization"
        },
        {
            "endOffset": 22205,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the context of emerging human H7N9 infections and before H7N9 strains were available for vaccine development, our study evaluated an H7N1 strain adjuvanted with AS03, providing a model for H7-subtype influenza vaccines.",
            "startOffset": 21983,
            "title": "Introduction"
        },
        {
            "endOffset": 30094,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "SCR was defined as the percentage of participants with either a pre-vaccination titer <1:10 and post-vaccination titer \u22651:40, or pre-vaccination titer \u22651:10 and \u22654-fold increase in post-vaccination titer.",
            "startOffset": 29890,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32968,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The incidence of redness and swelling at the injection site was low and no grade-3 redness or swelling was reported.",
            "startOffset": 32852,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32760,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The most commonly reported injection site symptom was pain (Fig. 4A), which was more frequent in vaccine recipients (41.7%\u201365.0%) than in placebo recipients (6.7%).",
            "startOffset": 32596,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23629,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.ClinicalTrials.gov (NCT01949090) and available at http://www.gsk-clinicalstudyregister.com (study ID: 200613).",
            "startOffset": 23488,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37785,
            "parents": [],
            "secId": "s0080",
            "sentence": "We assessed the immune response up to 12 months post dose 1.",
            "startOffset": 37725,
            "title": "Discussion"
        },
        {
            "endOffset": 23487,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant before any study procedure.",
            "startOffset": 23400,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Participants were randomized (1:1:1:1:2) to receive 1 of 4 H7N1 vaccine formulations, or saline placebo.",
            "startOffset": 23645,
            "title": "Randomization"
        },
        {
            "endOffset": 29815,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "A seronegative participant was defined as having an antibody titer below the cut-off.",
            "startOffset": 29730,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40615,
            "parents": [],
            "secId": "s0080",
            "sentence": "Cross-reactivity against H7N9 was observed by HI and MN assays.",
            "startOffset": 40552,
            "title": "Discussion"
        },
        {
            "endOffset": 24496,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The trial was conducted in an observer-blind manner; all participants, the sponsor and those responsible for evaluation of any study endpoint were unaware of the administered product.",
            "startOffset": 24313,
            "title": "Blinding"
        },
        {
            "endOffset": 29621,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "GMT calculations were performed by taking the anti-log of the mean of the log10 transformed inverse titers.",
            "startOffset": 29514,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41800,
            "parents": [],
            "secId": "s0090",
            "sentence": "The CEO/owner of CRG received payment as per guidelines to present papers at conferences.",
            "startOffset": 41711,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 22978,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The vaccine or placebo was administered as a 2-dose series at days 0 and 21.",
            "startOffset": 22902,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23098,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study comprised 5 additional visits (day 7, 28, 42, and month 6 and 12), and 2 telephone contacts at month 3 and 9.",
            "startOffset": 22979,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39647,
            "parents": [],
            "secId": "s0080",
            "sentence": "Tolerability of the vaccine seemed to be acceptable, as a high adherence (97.8%) to the 2-dose vaccination schedule was observed.",
            "startOffset": 39518,
            "title": "Discussion"
        },
        {
            "endOffset": 34916,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Four participants (1 in the 3.75A and placebo groups, and 2 in the 7.5B group) experienced an SAE leading to withdrawal from the study; one of these participants had a spontaneous pneumothorax which resolved after 26 days, while the other 3 participants had a fatal SAE (acute kidney injury and sepsis; metastatic colon cancer; and lung cancer).",
            "startOffset": 34571,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 26439,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "HI antibody titers were measured on serially-diluted serum samples with a standardized and comprehensively validated HI assay using 4 HI units of the appropriate antigen and an erythrocyte suspension at an adequate concentration.",
            "startOffset": 26210,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31461,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The antibody response tended to be the highest for the AS03A-adjuvanted formulations.",
            "startOffset": 31376,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 41710,
            "parents": [],
            "secId": "s0090",
            "sentence": "MF\u2019s wife is CEO/owner of CRG and they have conducted numerous clinical trials with multiple sponsors over the last ten years.",
            "startOffset": 41584,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 23134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Safety was assessed at every visit.",
            "startOffset": 23099,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42199,
            "parents": [],
            "secId": "s0095",
            "sentence": "The corresponding author was responsible for submission of the publication.",
            "startOffset": 42124,
            "title": "Author contribution"
        },
        {
            "endOffset": 29889,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "SPR was defined as the percentage of participants with an HI titer \u22651:40.",
            "startOffset": 29816,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35234,
            "parents": [],
            "secId": "s0080",
            "sentence": "This phase II trial was the first assessment of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older, which may serve as a model for the development of other H7 subtype vaccines.",
            "startOffset": 35041,
            "title": "Discussion"
        },
        {
            "endOffset": 37182,
            "parents": [],
            "secId": "s0080",
            "sentence": "Despite the higher immune response with the double H5N1 dose, licensing criteria were easily met with the single dose formulation following a 2-dose administration schedule.",
            "startOffset": 37009,
            "title": "Discussion"
        },
        {
            "endOffset": 33317,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Unsolicited AEs were reported by \u226436.7% of participants per group.",
            "startOffset": 33251,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 21269,
            "parents": [],
            "secId": "s0005",
            "sentence": "Despite the development of antiviral drugs, vaccination remains an effective way of controlling influenza.",
            "startOffset": 21163,
            "title": "Introduction"
        },
        {
            "endOffset": 40041,
            "parents": [],
            "secId": "s0080",
            "sentence": "The formulation is immunogenic at antigen-sparing doses (3.75 \u03bcg HA), which is crucial for pandemic vaccines.",
            "startOffset": 39932,
            "title": "Discussion"
        },
        {
            "endOffset": 41270,
            "parents": [],
            "secId": "s0085",
            "sentence": "GlaxoSmithKline Biologicals SA paid for costs associated with the development and the publishing of the present manuscript.",
            "startOffset": 41147,
            "title": "Funding"
        },
        {
            "endOffset": 32190,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "VRR measured with the MN assay was highest at 21 days post dose 2, ranging from 46.4% in the H7N1-7.5B group to 81.5% in the H7N1-3.75A group (Fig. 3B).",
            "startOffset": 32038,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 35634,
            "parents": [],
            "secId": "s0080",
            "sentence": "Antibody responses tended to be the highest for the AS03A-adjuvanted formulations, likely due to the lower tocopherol content of AS03B.",
            "startOffset": 35499,
            "title": "Discussion"
        },
        {
            "endOffset": 21163,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 21162,
                    "startOffset": 21155
                },
                "b0015": {
                    "endOffset": 21049,
                    "startOffset": 21044
                },
                "b0020": {
                    "endOffset": 21162,
                    "startOffset": 21155
                },
                "b0025": {
                    "endOffset": 21162,
                    "startOffset": 21155
                }
            },
            "secId": "s0005",
            "sentence": "The seriousness of H7N9 cases increases with age [3,5], and a high fatality risk has been reported in patients older than 60 years compared to younger patients [2,4,5].",
            "startOffset": 20995,
            "title": "Introduction"
        },
        {
            "endOffset": 33111,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Headache, fatigue and muscle ache were the most commonly reported solicited general symptoms, with similar incidences across groups (Fig. 4B).",
            "startOffset": 32969,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28238,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Diary cards were used to capture solicited symptoms during the 7-day post-vaccination period and spontaneously reported adverse events (AEs) up to 21 days post vaccination.",
            "startOffset": 28066,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 29278,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Immunogenicity analyses were performed on the per-protocol (PP) cohort for immunogenicity, including all participants who met all eligibility criteria, had received 2 study doses, complied with protocol procedures, and had available assay results for H7N1 antibodies.",
            "startOffset": 29011,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33932,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "AEs with medically attended visit were reported by 23 (38.3%) participants in the H7N1-3.75B group, 29 (48.3%) in the H7N1-3.75A group, 31 (51.7%) in the H7N1-7.5B group, 22 (36.7%) in the H7N1-7.5A group, and 49 (40.8%) in the placebo group.",
            "startOffset": 33690,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38494,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 38493,
                    "startOffset": 38489
                }
            },
            "secId": "s0080",
            "sentence": "Reactivity against North American H7 virus was not assessed in this study, however preclinal data showed that AS03-adjuvanted H7N1 vaccine induced robust serum antibody responses against other H7 viruses from both the Eurasian and North American lineages including H7N9, H7N7 and H7N3 viruses [14].",
            "startOffset": 38196,
            "title": "Discussion"
        },
        {
            "endOffset": 28387,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Serious adverse events (SAEs), AEs with medically attended visit, and potential immune-mediated diseases (pIMDs) were recorded throughout the study.",
            "startOffset": 28239,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 39134,
            "parents": [],
            "secId": "s0080",
            "sentence": "Injection-site pain was reported by 41.7%\u201365.0% of participants in the vaccine groups, but less than 3.3% of participants reported grade-3 pain.",
            "startOffset": 38990,
            "title": "Discussion"
        },
        {
            "endOffset": 40364,
            "parents": [],
            "secId": "s0080",
            "sentence": "A formulation containing the same dose of HA and AS03 has been licensed for H5N1 in adults.",
            "startOffset": 40273,
            "title": "Discussion"
        },
        {
            "endOffset": 42040,
            "parents": [],
            "secId": "s0095",
            "sentence": "All authors participated in the design, implementation or analysis, or the interpretation of the study, and in the development of this manuscript.",
            "startOffset": 41894,
            "title": "Author contribution"
        },
        {
            "endOffset": 35499,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 35498,
                    "startOffset": 35495
                }
            },
            "secId": "s0080",
            "sentence": "All adjuvanted formulations elicited an immune response after 2 doses; 21 days post-dose 2, SPR and SCR were in line with those reported for an AS03A-adjuvanted H5N1 vaccine in adults \u226565 years of age (SPR: 74.5% [95% CI: 69.9; 78.7], SCR: 74.0% [69.4; 78.2]) [9].",
            "startOffset": 35235,
            "title": "Discussion"
        },
        {
            "endOffset": 31130,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Baseline characteristics were balanced in the vaccine and placebo groups (Table 1).",
            "startOffset": 31047,
            "title": "Study population"
        },
        {
            "endOffset": 38804,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 38803,
                    "startOffset": 38796
                },
                "b0080": {
                    "endOffset": 38803,
                    "startOffset": 38796
                },
                "b0085": {
                    "endOffset": 38803,
                    "startOffset": 38796
                }
            },
            "secId": "s0080",
            "sentence": "It has been suggested that effectiveness of influenza vaccines could be better evaluated with cell-mediated immune responses used complementarily to antibody titers, especially in an elderly population [15\u201317].",
            "startOffset": 38594,
            "title": "Discussion"
        },
        {
            "endOffset": 41361,
            "parents": [],
            "secId": "s0090",
            "sentence": "AM, DF, JS, PL, BLI and AS are employees of the GSK group of companies.",
            "startOffset": 41290,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 21706,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 21705,
                    "startOffset": 21702
                }
            },
            "secId": "s0005",
            "sentence": "Therefore, improved vaccines are needed for older age groups to stimulate both cellular and humoral immunity [6].",
            "startOffset": 21593,
            "title": "Introduction"
        },
        {
            "endOffset": 26966,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Antibody geometric mean titers (GMTs), seropositivity rates, mean geometric increase (MGI), seroconversion rate (SCR) and seroprotection rate (SPR) were evaluated with 95% confidence intervals (CIs).",
            "startOffset": 26767,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 38195,
            "parents": [],
            "secId": "s0080",
            "sentence": "The adjuvanted H7N1 vaccine induced comparable level of cross-reactive serum antibody to the tested vaccine-heterologous strains (H7N9 Eurasian lineage).",
            "startOffset": 38042,
            "title": "Discussion"
        },
        {
            "endOffset": 21894,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21893,
                    "startOffset": 21890
                }
            },
            "secId": "s0005",
            "sentence": "Moreover, even in younger adults, H7 vaccines have been found to be suboptimally immunogenic in a study in the US; inclusion of an adjuvant dramatically improved their immunogenicity [7].",
            "startOffset": 21707,
            "title": "Introduction"
        },
        {
            "endOffset": 26766,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "HI titers <10 were considered to be below the assay cut-off.",
            "startOffset": 26706,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 29514,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "An adapted PP cohort was defined, which includes PP day 42 cohort for day 0, 21 and 42 immunogenicity data analysis; PP month 6 cohort for month 6 immunogenicity data analysis; and PP month 12 for month 12 immunogenicity data analysis.",
            "startOffset": 29279,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33460,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Unsolicited AEs considered by the investigator to be causally related to vaccination were reported by 13 participants (Supplementary Table 1).",
            "startOffset": 33318,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36214,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 36129,
                    "startOffset": 36125
                },
                "b0055": {
                    "endOffset": 36143,
                    "startOffset": 36139
                }
            },
            "secId": "s0080",
            "sentence": "These findings are in line with observations made with AS03-adjuvanted H5N1 [10] and H7N9 [11] vaccine formulations, for which AS03B tended to perform less strongly.",
            "startOffset": 36049,
            "title": "Discussion"
        },
        {
            "endOffset": 38042,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 38041,
                    "startOffset": 38037
                }
            },
            "secId": "s0080",
            "sentence": "While antibody titers had declined by month 12, it can be hypothesized that vaccinees were primed adequately, and are likely to show an anamnestic response to a booster dose as seen with AS03-adjuvanted H5N1 vaccine up to 3 years after 2-dose priming [13].",
            "startOffset": 37786,
            "title": "Discussion"
        },
        {
            "endOffset": 26705,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Serum pre-treatment procedure was adapted (adding a receptor-destroying enzyme treatment step after horse red blood cell hemadsorption) to remove nonspecific agglutinins of horse red blood cells and nonspecific virus inhibitors introduced by the hemadsorption step.",
            "startOffset": 26440,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 27116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The titer of virus neutralizing antibodies in serum was determined by a MN assay, performed on a subset of participants from each group up to month 6.",
            "startOffset": 26966,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 37528,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 37439,
                    "startOffset": 37433
                },
                "b0055": {
                    "endOffset": 37439,
                    "startOffset": 37433
                }
            },
            "secId": "s0080",
            "sentence": "Immune responses post dose 1 were low, as also observed for H7N9 vaccine formulations [7,11], indicating the need for a 2-dose vaccination schedule to achieve robust immunogenicity.",
            "startOffset": 37347,
            "title": "Discussion"
        },
        {
            "endOffset": 32851,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The incidence of grade-3 injection-site pain was low (\u22643.3% of participants in any group).",
            "startOffset": 32761,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 22445,
            "parents": [],
            "secId": "s0005",
            "sentence": "The trial assessed the immunogenicity and safety of different vaccine formulations comprising H7N1 split-virus inactivated hemagglutinin (HA) antigen (A/mallard/Netherlands/12/2000) adjuvanted with AS03 in adults 65 years of age and older.",
            "startOffset": 22206,
            "title": "Introduction"
        },
        {
            "endOffset": 31831,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "SPR, SCR and MGI were also low 21 days post dose 1 and followed the same trend as the GMT values over time (Table 2).",
            "startOffset": 31714,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 32037,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The antibody response assessed by MN assay showed a similar pattern as the HI immune response, with titers at month 6 remaining 1.8\u20132.7-fold above baseline levels, depending on the vaccine group (Fig. 3A).",
            "startOffset": 31832,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 31566,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "At 21 days post-dose 1, the immune response to the H7N1 vaccine strain was low across all vaccine groups.",
            "startOffset": 31461,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 34570,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Forty participants reported 67 SAEs; none were considered by the investigator to be vaccination-related, and most resolved or were resolving by study end (Supplementary Table 2).",
            "startOffset": 34392,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37008,
            "parents": [],
            "secId": "s0080",
            "sentence": "This is in contrast to our study, where the 7.5 \u03bcg H7N1 HA formulation contained the same amount of adjuvant as the respective 3.75 \u03bcg formulation.",
            "startOffset": 36861,
            "title": "Discussion"
        },
        {
            "endOffset": 27232,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 27231,
                    "startOffset": 27228
                }
            },
            "secId": "s0040",
            "sentence": "The MN assay was performed on heat-treated sera using Madin-Darby Canine Kidney cells, as previously described [8].",
            "startOffset": 27117,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 41470,
            "parents": [],
            "secId": "s0090",
            "sentence": "AM, DF, PL, BLI, PR and AS hold shares in the GSK group of companies as part of their employee remuneration.",
            "startOffset": 41362,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 34196,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Two pIMDs were identified using a pre-specified list of terms for retrieving events that could have an autoimmune origin: radiculitis with onset 10 days after the first H7N1-3.75B dose, and VIIth nerve paralysis with onset 365 days after the first H7N1-7.5A dose.",
            "startOffset": 33933,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28582,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "SAEs were defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolonged existing hospitalization, or resulted in disability or incapacity.",
            "startOffset": 28388,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 36277,
            "parents": [],
            "secId": "s0080",
            "sentence": "There was no clear impact of HA content on the immune response.",
            "startOffset": 36214,
            "title": "Discussion"
        },
        {
            "endOffset": 40272,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 40271,
                    "startOffset": 40268
                }
            },
            "secId": "s0080",
            "sentence": "The AS03A-containing formulations retain an acceptable reactogenicity profile, while such formulations may be expected to offer a somewhat better immunogenicity (best MGI) to older individuals and those with chronic illnesses [9].",
            "startOffset": 40042,
            "title": "Discussion"
        },
        {
            "endOffset": 40551,
            "parents": [],
            "secId": "s0080",
            "sentence": "In conclusion, 2-dose vaccination of adults \u226565 years with AS03-adjuvanted H7N1 vaccine formulations elicited a strong humoral immune response with a clinically acceptable safety profile.",
            "startOffset": 40364,
            "title": "Discussion"
        },
        {
            "endOffset": 34392,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Both events had resolved by study end, and none were considered by the investigator to be vaccination-related.",
            "startOffset": 34282,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 21393,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccine development is an essential component of the World Health Organization\u2019s global strategy for pandemic preparedness.",
            "startOffset": 21270,
            "title": "Introduction"
        },
        {
            "endOffset": 33251,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The incidence of grade-3 solicited general symptoms was low (\u22645.0% of participants in any group for any of the solicited general symptoms).",
            "startOffset": 33112,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41875,
            "parents": [],
            "secId": "s0090",
            "sentence": "DS has nothing to disclose.",
            "startOffset": 41848,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 39931,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 39930,
                    "startOffset": 39926
                }
            },
            "secId": "s0080",
            "sentence": "Our results support the selection of formulations containing 3.75 \u03bcg HA adjuvanted with the higher AS03 dose (AS03A) for further development of H7-subtype vaccines, along with another H7N1 study in younger adults (reported elsewhere) and evaluations of H7N9 vaccine formulations [11].",
            "startOffset": 39647,
            "title": "Discussion"
        },
        {
            "endOffset": 25279,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Placebo was phosphate-buffered saline.",
            "startOffset": 25241,
            "title": "Study vaccine"
        },
        {
            "endOffset": 38989,
            "parents": [],
            "secId": "s0080",
            "sentence": "Overall, all formulations were well tolerated.",
            "startOffset": 38943,
            "title": "Discussion"
        },
        {
            "endOffset": 27853,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Vaccine-homologous strain A/mallard/Netherlands/12/2000 was used for both HI and MN assays, and vaccine-heterologous strains A/Shanghai/2/2013 and A/Anhui/1/2013 were used for HI and MN, respectively.",
            "startOffset": 27653,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31375,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "SPRs in the different vaccinated groups were 69.6%\u201388.7%, SCRs 69.6%\u201388.5%, and MGI 11.0\u201318.9.",
            "startOffset": 31281,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 27479,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The neutralizing titer corresponded to the highest serum dilution able to neutralize 50% of the virus; in practice, this titer corresponds to the GMT between the last dilution without haemagglutination (100% neutralization) and the next dilution.",
            "startOffset": 27233,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 27652,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "MN antibody GMTs, seropositivity rates, and vaccine response rates (VRRs) were evaluated with 95% CIs.",
            "startOffset": 27550,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 38943,
            "parents": [],
            "secId": "s0080",
            "sentence": "Nevertheless, we observed a notable increase in immune response from dose 1 to dose 2, which indicates the induction of a T-cell response.",
            "startOffset": 38805,
            "title": "Discussion"
        },
        {
            "endOffset": 24870,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Product preparation and administration was done by authorized medical personnel who did not participate in any study clinical evaluations or in preparation of biological specimens.",
            "startOffset": 24690,
            "title": "Blinding"
        },
        {
            "endOffset": 28065,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Blood samples for clinical safety laboratory (hematology/biochemistry) evaluations were drawn at days 0, 7, 21, 28, and 42.",
            "startOffset": 27942,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 36860,
            "parents": [],
            "secId": "s0080",
            "sentence": "However, in that H5N1 study, the double (7.5 \u03bcg) dose was achieved by simultaneously administering 2 single doses, meaning that the participants not only received a double dose of HA antigen but also of the adjuvant.",
            "startOffset": 36644,
            "title": "Discussion"
        },
        {
            "endOffset": 39517,
            "parents": [],
            "secId": "s0080",
            "sentence": "Similar safety and reactogenicity profiles were observed between formulations, regardless of HA dose or adjuvant.",
            "startOffset": 39404,
            "title": "Discussion"
        },
        {
            "endOffset": 41146,
            "parents": [],
            "secId": "s0085",
            "sentence": "GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis.",
            "startOffset": 41054,
            "title": "Funding"
        },
        {
            "endOffset": 20922,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20806,
                    "startOffset": 20803
                },
                "b0010": {
                    "endOffset": 20921,
                    "startOffset": 20918
                }
            },
            "secId": "s0005",
            "sentence": "In 2013, a novel avian influenza virus (H7N9) caused human infections in China [1] with high morbidity and mortality (295 deaths among 730 laboratory-confirmed cases, reported up to March 2016) [2].",
            "startOffset": 20724,
            "title": "Introduction"
        },
        {
            "endOffset": 30672,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Statistical analyses were performed using Statistical Analysis System (SAS) version 9.22 on Windows.",
            "startOffset": 30572,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 23399,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol was approved by the independent ethics committee or institutional review board of each study center.",
            "startOffset": 23286,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27902,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "All strains were attenuated by reverse genetics.",
            "startOffset": 27854,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 32451,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Day 42 VRR assessed by MN assay ranged from 46.4% (H7N1-3.75B) to 85.2% (H7N1-3.75A) (Fig. 3).",
            "startOffset": 32357,
            "title": "Immune response to the cross-reactive H7N9 strain"
        },
        {
            "endOffset": 41847,
            "parents": [],
            "secId": "s0090",
            "sentence": "AT conducted several clinical trials with GSK.",
            "startOffset": 41801,
            "title": "Conflict of interest"
        }
    ],
    "docId": "S0264410X17302700",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Anu.2.Madan@gsk.com",
                "first": "Anuradha",
                "initial": "A.",
                "last": "Madan"
            },
            {
                "email": null,
                "first": "Murdo",
                "initial": "M.",
                "last": "Ferguson"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Rheault"
            },
            {
                "email": null,
                "first": "David",
                "initial": "D.",
                "last": "Seiden"
            },
            {
                "email": "azhar.toma@mannaresearch.com",
                "first": "Azhar",
                "initial": "A.",
                "last": "Toma"
            },
            {
                "email": "damien.j.friel@gsk.com",
                "first": "Damien",
                "initial": "D.",
                "last": "Friel"
            },
            {
                "email": null,
                "first": "Jyoti",
                "initial": "J.",
                "last": "Soni"
            },
            {
                "email": "ping.li4@pfizer.com",
                "first": "Ping",
                "initial": "P.",
                "last": "Li"
            },
            {
                "email": "bruce.2.innis@gsk.com",
                "first": "Bruce L.",
                "initial": "B.L.",
                "last": "Innis"
            },
            {
                "email": null,
                "first": "Anne",
                "initial": "A.",
                "last": "Schuind"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.02.057",
        "firstpage": "1865",
        "issn": "0264410X",
        "keywords": [
            "AS03 adjuvant",
            "Elderly population",
            "H7 influenza vaccine",
            "H7N1",
            "H7N9",
            "Pandemic flu"
        ],
        "lastpage": "1872",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65\u00a0years of age and older: A phase II, observer-blind, randomized, controlled trial"
    }
}